Bulletin: Despite domestic snubbing, AbCellera made nearly $200 million off of its COVID-19 treatment
Plus, it generated a net profit of $119 million USD, up from a net loss of $2 million on $11.6 million in revenue.
Vancouver’s AbCellera closed out a monster year in which it became Canada’s most valuable biotech company by growing year-over-year revenue 1,908% to $233 million USD.
The company announced Tuesday (March 29) that it generated a net profit of $119 million USD, up from a net loss of $2 million on $11.6 million in revenue in 2019.
“AbCellera had a breakthro…